SUCCESSFUL TREATMENT OF MILD TO MODERATE ACNE VULGARIS WITH DR MICHAELS® (also branded as ZITINEX®) TOPICAL PRODUCTS FAMILY: A CLINICAL TRIAL


1Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; 2Psoriasis & Skin Clinic, Melbourne, Australia; 32nd Medical Faculty, Charles University, Bulovka Hospital, 4Institute of Clinical and Experimental Medicine, Prague, Czech Republic; 5Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy; 6Dermatological Department University of Pisa, Pisa, Italy; 7Onkoderma– Polyclinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 8Department of Dermatology and Venerology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria; 9Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venerology and Dermatologic Surgery, Sofia, Bulgaria; 10PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague I, Czech Republic; 11University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India; 12Department “Medicinal Information and Non-interventional studies”, Bulgarian Drug Agency, Sofia, Bulgaria; 13Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; 14Centro Studi per la Ricerca Multidisciplinare e Rigenaritiva, Università Degli Studi “G. Marconi”, Rome, Italy; 15Chair of Dermatology, University of Rome “G. Marconi” Rome, Italy

Acne vulgaris is an epidemic inflammatory skin disease of multi-factorial origin, frequently seen in adolescents and often persisting or occurring through to adulthood. Acne vulgaris is a nearly universal skin disease afflicting 79-95% of the adolescent population in westernized societies and is a significant cause of psychological morbidity in affected patients. Despite the various treatment options available for acne, there is still a need for a safe and effective option. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Zitinex®) product family in the treatment of papulo-pustular acne. 25 patients (17 female/8 male), aged 15-22, with a mild to moderate papulo-pustular acne, localized on the face and on the trunk, were included in this study. None of the patients had used any other kind of treatment in the 3 months prior to commencing this study. All of the patients were treated with Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, a cream, PSC 200 and PSC 900 oral supplements. Application time of Dr Michaels® (Zitinex®) products was 12 weeks. The treatment was been evaluated clinically at 0, 4, 8 and 12 weeks. All of the patients showed an improvement in all parameters of their acne (comedones, papules, pustules, hyperpigmentation and scars). The acne lesions and erythema had mostly resolved. The hyperpigmentation and pitted scarring had significantly reduced also, with the skin appearing smoother. The treatment was well tolerated and no side effects have been described. Our study demonstrates that the Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, cream and oral supplements PSC 200 and PSC 900 are an effective therapeutic option for the treatment of moderately severe acne vulgaris. Moreover, it highlights the safety profile of the Dr Michaels® (Zitinex®) product family in a case of acne compared to traditional first-line treatments.